The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism

Redox Report

Volumn 8, Issue 1, 2003, Pages 41-46

  Bernard, Dirk ^a   Christophe, Armand ^a   Delanghe, Joris ^a   Langlois, Michel ^a   De Buyzere, Marc ^a   Comhaire, Frank ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; COPPER ION; HAPTOGLOBIN; LOW DENSITY LIPOPROTEIN; PLACEBO; QUATRAL; SELENIUM; ZINC;

ADULT; AGED; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GEL ELECTROPHORESIS; GENETIC POLYMORPHISM; HUMAN; HYPOTHESIS; IN VITRO STUDY; INDIVIDUALITY; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; MODULATION; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

AGED; ALLELES; ANTIOXIDANTS; COPPER; DIETARY SUPPLEMENTS; FEMALE; HAPTOGLOBINS; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDANTS; OXIDATIVE STRESS; OXYGEN; PHENOTYPE; PLACEBOS; POLYMORPHISM, GENETIC; RANDOM ALLOCATION; TIME FACTORS;

EID: 0037279021     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100003125001233     Document Type: Review

References (35)

1. Westhuyzen J. The oxidation hypothesis of atherosclerosis: an update. Ann Clin Lab Sci 1997; 27: 1-10.
2. Schwenke DC. Antioxidants and atherogenesis. J Nutr Biochem 1998; 9: 424-445.
3. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20: 707-727.
4. Devaraj S, Jialal I. Oxidized low-density lipoprotein and atherosclerosis. Int J Clin Lab Res 1996; 26: 178-184.
5. Esterbauer H, Dieber-Rotheneder M, Waeg G, Puhl H, Tatzber F. Endogenous antioxidants and lipoprotein oxidation. Biochem Soc Trans 1990; 18: 1059-1061.
6. Jialal I, Vega GL, Grundy SM. Physiologic levels of ascorbate inhibit the oxidative modification of low density lipoprotein. Atherosclerosis 1990; 82: 185-191.
7. Fuller CJ, Grundy SM, Norkus EP, Jialal I. Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers. Atherosclerosis 1996; 119: 139-150.
8. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vivo oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6: 67-75.
9. Jialal I, Norkus EP, Cristol L, Grundy SM. Beta-carotene inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1993; 1086: 134-138.
10. Noguchi N, Niki E. Dynamics of vitamin E action against LDL oxidation. Free Radic Res 1998; 28: 561-572.
11. Gey FK. Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Biofactors 1998; 7: 113-174.
12. Niki E, Noguchi N, Tsuchihashi H, Gotoh H. Interaction among vitamin C, vitamin E, and β-carotene. Am J Clin Nutr 1995; 62 (Suppl): 1322S-1326S.
13. Fang JC, Kinlay S, Beltrame J et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet 2002; 359: 1108-1113.
14. Hennekens CH, Gaziano JM, Manson JE, Buring JE. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Am J Clin Nutr 1995; 62 (Suppl): 1377S-1380S.
15. Hercberg S, Galan P, Preziosi P et al. Background and rationale behind the SU.VI.MAX study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. Int J Vit Nutr Res 1998; 68: 3-20.
16. Allard JP, Royall D, Kurian R, Muggli R, Jeejeebhoy KN. Effects of beta-carotene supplementation on lipid peroxidation in humans. Am J Clin Nutr 1994; 59: 884-890.
17. Wen Y, Cooke T, Feely J. The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation. Br J Clin Pharmacol 1997; 44: 94-97.
18. Langlois M, Delanghe J. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 1589-1600.
19. Langlois MR, Delanghe JR, De Buyzere ML, Bernard DR, Ouyang J. Effect of haptoglobin on the metabolism of vitamin C. Am J Clin Nutr 1997; 66: 606-610.
20. Delanghe J, Cambier B, Langlois M et al. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis 1997; 132: 215-219.
21. Chapelle JP, Albert A, Smeets JP, Heusghem C, Kulbertus HE. Effect of the haptoglobin phenotype on the size of a myocardial infarct. N Engl J Med 1982; 307: 457-463.
22. Delanghe J, Langlois M, Duprez D, De Buyzere M, Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 1999; 145: 287-292.
23. Nakhoul FM, Zoabi R, Kanter Y et al. Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001; 44: 602-604.
24. Smithies O. Zone electrophoresis in starch gels: group variations in the serum proteins of normal human adults. Biochem J 1955; 61: 629-641.
25. Fink PC, Roemer M, Haeckel R et al. Measurement of proteins with the Behring nephelometer. J Clin Chem Clin Biochem 1989; 27: 261-276.
26. Leonhardt W, Hanefeld M, Schaper F. Diminished susceptibility to in vitro oxidation of low density lipoproteins in hypercholesterolemia: key role of alpha-tocopherol content. Atherosclerosis 1999; 144: 103-107.
27. Ramos P, Gieseg SP, Schuster B, Esterbauer H. Effect of temperature and phase transition on oxidation resistance of low density lipoprotein. J Lipid Res 1995; 36: 2113-2128.
28. Puhl H, Waeg H, Esterbauer H. Methods to determine oxidation of low-density proteins. Methods Enzymol 1994; 233: 425-441.
29. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 1996; 347: 781-786.
30. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 432: 154-160.
31. Melamed-Frank M, Lache O, Enav BI et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood 2001; 98: 3693-3698.
32. Madsen M, Graversen JH, Moestrup SK. Haptoglobin and CD163: captor and receptor gating hemoglobin to macrophage lysosomes. Redox Report 2001; 6: 386-388.
33. Graversen JH, Madsen M, Moestrup SK. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol 2002; 34: 309-314.
34. Preziosi P, Galan P, Herbeth B et al. Effects of supplementation with a combination of antioxidant vitamins and trace elements, at nutritional doses, on biochemical indicators and markers of the antioxidant system in adult subjects. J Am Coll Nutr 1998; 17: 244-249.
35. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.